Alzheimer's disease, a type of dementia that profoundly alters a person’s memory and cognitive function, affects an estimated ...

Blood tests and the adoption of AI in cognitive decline screenings have opened the door to new avenues for testing cognitive ...

These various tests are at different stages of validation – assuring they’re accurate across many different populations. And, for each protein, there are several different met ...

Researchers have developed a test that spots early signs of Alzheimer's disease. Rather than looking for amyloid-beta plaques ...

Alzheimer’s disease — which affects an estimated 7 million Americans — is notoriously difficult to detect, especially in its ...

At the Human Amyloid Imaging (HAI) meeting, held January 15-17, researchers focused on new techniques—all based on tau and ...

In related news, other scientists recently reported that phospho-tau isoforms in the CSF mirror protofibrillar forms of tau, ...

Now, several publications and presentations at the recent Alzheimer’s Association International Conference have demonstrated that blood tests measuring amyloid and tau proteins have become much more ...

Currently, although brain Abeta accumulation can be detected by positron emission tomography(4) (amyloid PET) and cerebrospinal fluid testing(5) (CSF testing), the high cost and invasiveness of ...

A new biomarker test can detect early-stage tau protein clumping up to a decade before it appears on brain scans, improving ...

Study finds that disease-modifying therapies for Alzheimer’s, lecanemab and donanemab, can extend independence in daily ...

More than 2 years since the original trial data for lecanemab in Alzheimer's disease was published,1 and over 1·5 years since approval by the US Food and Drug Administration, brain volume data have ...